| 30/03/26 | 07:30:00 | 30 Mar 2026 | | Suspension - Faron Pharmaceuticals Oy |
| 03/03/25 | 12:05:33 | 3 Mar 2025 | | FDA Grants Orphan Drug Designation |
| 28/02/25 | 12:00:00 | 28 Feb 2025 | | Notice of Annual General Meeting |
| 27/02/25 | 07:30:00 | 27 Feb 2025 | | Positive EMA Opinion on Orphan Drug Designation |
| 27/02/25 | 07:15:01 | 27 Feb 2025 | | Annual Report 2024 published |
| 27/02/25 | 07:00:12 | 27 Feb 2025 | | Financial Statement 1 January to 31 December 2024 |
| 19/02/25 | 10:00:00 | 19 Feb 2025 | | Notice of Financial Statement and Annual Report |
| 14/02/25 | 12:00:00 | 14 Feb 2025 | | Holding(s) in Company |
| 11/02/25 | 07:30:00 | 11 Feb 2025 | | Change of Broker |
| 06/02/25 | 15:00:00 | 6 Feb 2025 | | Holding(s) in Company |
| 06/02/25 | 07:00:06 | 6 Feb 2025 | | Results of Oversubscribed Placing |
| 05/02/25 | 16:30:00 | 5 Feb 2025 | | Proposed Issue and Placing |
| 31/01/25 | 07:00:07 | 31 Jan 2025 | | Final Patient Identified for BEXMAB Phase II Study |
| 13/12/24 | 07:00:02 | 13 Dec 2024 | | Faron’s Financial Calendar for 2025 |
| 10/12/24 | 07:00:07 | 10 Dec 2024 | | Faron presents BEXMAB data at ASH Annual Meeting |
| 02/12/24 | 08:00:00 | 2 Dec 2024 | | Interactions with UK Regulatory Authorities |
| 27/11/24 | 07:00:10 | 27 Nov 2024 | | Positive Phase 2 Interim Results from BEXMAB Trial |
| 11/11/24 | 07:00:10 | 11 Nov 2024 | | Targeting Soluble Clever-1 for Autoimmune Diseases |
| 05/11/24 | 07:00:03 | 5 Nov 2024 | | Shareholders’ Nomination Board |
| 22/10/24 | 07:00:03 | 22 Oct 2024 | | Faron’s Capital Markets Day 2024 |
| 07/10/24 | 07:00:09 | 7 Oct 2024 | | Faron announces Capital Markets Day |
| 30/08/24 | 07:00:14 | 30 Aug 2024 | | Grant of options |
| 27/08/24 | 07:00:12 | 27 Aug 2024 | | Faron 2024 Half-Year Financial Results |
| 27/08/24 | 07:00:12 | 27 Aug 2024 | | FDA Grants Fast Track Designation for Bexmarilimab |
| 20/08/24 | 07:00:17 | 20 Aug 2024 | | Notice of Half-Year Financial Results |
| 13/08/24 | 07:00:12 | 13 Aug 2024 | | Traumakine Research Collaboration and DoD Grant |
| 08/08/24 | 07:00:13 | 8 Aug 2024 | | Appointment of Chief Financial Officer |
| 07/08/24 | 10:00:00 | 7 Aug 2024 | | Grant of options |
| 06/08/24 | 08:30:00 | 6 Aug 2024 | | Faron Appoints Dr. Petri Bono as new CMO |
| 11/07/24 | 07:00:07 | 11 Jul 2024 | | Faron Announces Positive FDA Feedback |
| 25/06/24 | 14:00:00 | 25 Jun 2024 | | Update on settlement |
| 25/06/24 | 10:30:01 | 25 Jun 2024 | | Holding(s) in Company - Replacement |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company |
| 24/06/24 | 12:45:01 | 24 Jun 2024 | | Holding(s) in Company |
| 20/06/24 | 13:00:00 | 20 Jun 2024 | | New shares registered with Finnish Trade Register |
| 20/06/24 | 07:00:08 | 20 Jun 2024 | | Fully subscribed EUR 30.7 million share offering |
| 05/06/24 | 08:00:00 | 5 Jun 2024 | | Proposed REX Retail Offer |
| 04/06/24 | 07:00:09 | 4 Jun 2024 | | Faron commences a share offering |
| 20/05/24 | 07:00:08 | 20 May 2024 | | Initial positive data from Phase 2 of BEXMAB |
| 17/05/24 | 16:00:01 | 17 May 2024 | | Issuance of warrants |
| 16/05/24 | 07:05:20 | 16 May 2024 | | Founders named European Inventor Award finalists |
| 13/05/24 | 07:00:10 | 13 May 2024 | | Replacement – Board Change |
| 30/04/24 | 14:00:00 | 30 Apr 2024 | | Update on financial status |
| 30/04/24 | 13:00:00 | 30 Apr 2024 | | Board Change |
| 16/04/24 | 07:00:13 | 16 Apr 2024 | | Faron confirms plans under new leadership |
| 15/04/24 | 07:00:10 | 15 Apr 2024 | | Appointment of Chief Financial Officer |
| 08/04/24 | 07:10:01 | 8 Apr 2024 | | Approval of Warrant Terms and Conditions |
| 08/04/24 | 07:05:00 | 8 Apr 2024 | | Decisions of the Board of Directors |
